Impact of the Pro12Ala polymorphism of the PPAR?2 gene on diabetes and obesity in a highly consanguineous population

Abdulbari, Bener; Zirie, M.; Al-Hamaq, A. O. A. A.; Nawaz, Z.; Samson, N.; Mohammad, R.
January 2015
Indian Journal of Endocrinology & Metabolism;Jan/Feb2015, Vol. 19 Issue 1, p77
Academic Journal
Background: The peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor subfamily of transcription factors. It has been reported that they play important roles in obesity and the development of type 2 diabetes mellitus (T2DM). Materials and Methods: This case-control study was carried out among 764 Qatari patients with diabetes and 764 healthy subjects above 20 years of age at Primary Healthcare Clinics (PHCs) from January 2011 to December 2012. Face-to-face interviews were based on a questionnaire that included variables such as age, sex, sociodemographic status, body mass index (BMI) and other clinical parameters. The Pro12Ala in the PPARγ2 gene was detected on the LightCycler using two specific probes. Univariate and multivariate statistical analysis were performed. Results: The study revealed that in the diabetes group, Pro/(10.2% vs 9.4%; P = 0.606) and Ala/Ala (1.4% vs 0.9%; P = 0.343) were higher than in controls, whereas Pro/Pro (88.4% vs 89.7%;P = 0.413) was lower in diabetes patients, but no significant difference was observed among the genotype groups. In obese patients with diabetes, Pro/ Pro (89% vs 89.9%;P = 0.792) and Pro/Ala (8.9% vs 10.1%;P = 0.671) were lower than in obese healthy subjects. No homozygous Ala/Ala was found in obese healthy subjects, whereas 6 Ala/Ala homozygotes were in obese diabetes group. But in diabetes group, obese patients had higher homozygous of Pro/Pro (89.3% vs 87.8%;P = 0.523) and Ala/Ala (1.8% vs 1.2%;P = 0.771) compared to non-obese patients. Conclusion: The current study did not reveal an association between the Pro12Ala polymorphism of the PPAR γ2 gene and type 2 diabetes (T2D) in Qatari's population.


Related Articles

  • Future of newer basal insulin. Madhu, S. V.; Velmurugan, M. // Indian Journal of Endocrinology & Metabolism;Mar/Apr2013, Vol. 17 Issue 2, p249 

    Basal insulin have been developed over the years. In recent times newer analogues have been added to the armanentarium for diabetes therapy. This review specifically reviews the current status of different basal insulins

  • DIABETES MELLITUS AT PGI CIKINI HOSPITAL. Suekto, Gemin; Rahmatillah, Diana Laila; Efi, Aprilita Rinayanti; Lukas, Stefanus // Wood Industry / Drvna Industrija;2015 Supplement1, Vol. 6 Issue 1, p1622 

    Diabetes mellitus (DM) is a group of metabolic disorders characterized by hyperglycemia and abnormalities in carbohydrate, fat, and protein metabolism. It results from defects in insulin secretion, insulin sensitivity, or both. Chronic microvascular, macrovascular, and neuropathic complications...

  • Variation and association to diabetes in 2000 full mtDNA sequences mined from an exome study in a Danish population. Li, Shengting; Besenbacher, Soren; Li, Yingrui; Kristiansen, Karsten; Grarup, Niels; Albrechtsen, Anders; Sparsø, Thomas; Korneliussen, Thorfinn; Hansen, Torben; Wang, Jun; Nielsen, Rasmus; Pedersen, Oluf; Bolund, Lars; Schierup, Mikkel H // European Journal of Human Genetics;Aug2014, Vol. 22 Issue 8, p1040 

    In this paper, we mine full mtDNA sequences from an exome capture data set of 2000 Danes, showing that it is possible to get high-quality full-genome sequences of the mitochondrion from this resource. The sample includes 1000 individuals with type 2 diabetes and 1000 controls. We characterise...

  • Approach to the patient with atypical diabetes. Steenkamp, Devin W.; Alexanian, Sara M.; Sternthal, Elliot // CMAJ: Canadian Medical Association Journal;6/10/2014, Vol. 186 Issue 9, p678 

    The article examines the methods of diagnosing patients with atypical diabetes. Topics discussed include types of diabetes, difficulties in determining the type of diabetes that a patient may have and diagnostic factors that should be considered in determining atypical diabetes. Also discussed...

  • Metabolic disease: Obesity-associated mutations. Pola, Carolina // Nature Medicine;Dec2013, Vol. 19 Issue 12, p1582 

    The article reports the effect of kinase suppressor of Ras 2 (KSR2) in maintaining the homeostasis and glucose tolerance associated with obesity and impaired glucose metabolism in humans.

  • Effects of basal insulin application on serum visfatin and adiponectin levels in type 2 diabetes. WEI-DONG WANG; LIN XING; JUN-RU TENG; SHUO LI; NA MI // Experimental & Therapeutic Medicine;2015, Vol. 9 Issue 6, p2219 

    The aim of this study was to investigate the effects of basal insulin application on the serum visfatin and adiponectin (APN) levels of patients with type 2 diabetes mellitus (T2DM). A total of 200 patients with T2DM, who were diagnosed in The Third People's Hospital of Jinan (glycosylated...

  • Rosiglitazone protects against palmitate-induced pancreatic beta-cell death by activation of autophagy via 5′-AMP-activated protein kinase modulation. Wu, Jie; Wu, Jun-jie; Yang, Lin-jun; Wei, Li-xin; Zou, Da-jin // Endocrine (1355008X);Aug2013, Vol. 44 Issue 1, p87 

    Promoting beta-cell survival is crucial for the prevention of beta-cell failure in diabetes. Thiazolidinediones, a widely used drug to improve insulin sensitivity in clinical practice, is found to have a protective effect on islet beta-cell. To date, the mechanism underlying the protective role...

  • Aldose reductase C-106T gene polymorphism in type 2 diabetics with microangiopathy in Iranian individuals. Rezaee, Majid Reza Sheikh; Amiri, Ahmad Ahmadzadeh; Hashemi-Soteh, Mohammad Bagher; Daneshvar, Fatemeh; Emady-Jamaly, Roghaye; Jafari, Reza; Soleimani, Behyar; Haghiaminjan, Hamed // Indian Journal of Endocrinology & Metabolism;Jan/Feb2015, Vol. 19 Issue 1, p95 

    Background: Aldose reductase (AR) is the rate-limiting enzyme in the glucose metabolism, which has been implicated in the pathogenesis of diabetic microvascular complications (MVCs). Frequent C-106T polymorphism in the promoter of the AR gene may change the expression of the gene. Aims: The aim...

  • Common Variants in Maturity-Onset Diabetes of the Young Genes Contribute to Risk of Type 2 Diabetes in Finns. Bonnycastle, Lori L.; Willer, Cristen J.; Conneely, Karen N.; Jackson, Anne U.; Burrill, Cecily P.; Watanabe, Richard M.; Chines, Peter S.; Narisu, Narisu; Scott, Laura J.; Enloe, Sareena T.; Swift, Amy J.; Duren, William L.; Stringham, Heather M.; Erdos, Michael R.; Riebow, Nancy L.; Buchanan, Thomas A.; Valle, Timo T.; Tuomilehto, Jaakko; Bergman, Richard N.; Mohlke, Karen L. // Diabetes;Sep2006, Vol. 55 Issue 9, p2534 

    Prior reports have suggested that variants in the genes for maturity-onset diabetes of the young (MODY) may confer susceptibility to type 2 diabetes, but results have been conflicting and coverage of the MODY genes has been incomplete. To complement our previous studies of HNF4A, we examined the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics